Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Has Consensus Target Price of $8.06 According to Analysts

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been given an average recommendation of “Hold” by the five analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $8.06.

RXRX has been the topic of a number of research reports. Morgan Stanley set a $5.30 price objective on Recursion Pharmaceuticals in a report on Monday, August 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Friday, July 17th. Finally, Wall Street Zen raised shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 29th.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, CEO Najat Khan sold 22,408 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total transaction of $78,876.16. Following the completion of the sale, the chief executive officer owned 2,072,890 shares in the company, valued at approximately $7,296,572.80. This represents a 1.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 50,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $4.84, for a total transaction of $242,000.00. Following the completion of the transaction, the director directly owned 6,108,287 shares in the company, valued at approximately $29,564,109.08. This represents a 0.81% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 157,408 shares of company stock worth $643,576 over the last three months. Corporate insiders own 6.65% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

Hedge funds have recently modified their holdings of the company. MCF Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals in the 2nd quarter worth approximately $27,000. Integral Investment Advisors Inc. acquired a new stake in Recursion Pharmaceuticals during the 1st quarter valued at $39,000. MQS Management LLC acquired a new position in Recursion Pharmaceuticals in the first quarter worth $41,000. Fund Advisors of America Inc FL bought a new stake in shares of Recursion Pharmaceuticals during the second quarter worth $45,000. Finally, QRG Capital Management Inc. bought a new stake in shares of Recursion Pharmaceuticals during the first quarter worth $47,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Trading Down 2.6%

Recursion Pharmaceuticals stock traded down $0.10 during midday trading on Tuesday, reaching $3.90. The stock had a trading volume of 3,680,416 shares, compared to its average volume of 19,107,188. Recursion Pharmaceuticals has a twelve month low of $2.77 and a twelve month high of $7.18. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 5.03. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of -3.79 and a beta of 1.04. The firm’s fifty day simple moving average is $3.59 and its two-hundred day simple moving average is $3.40.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. The firm had revenue of $7.67 million during the quarter, compared to analysts’ expectations of $10.97 million. During the same quarter last year, the firm earned ($0.41) EPS. Equities analysts anticipate that Recursion Pharmaceuticals will post -0.94 EPS for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.

Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience.